- Home
- LSTA vs EVAX Comparison
LSTA vs EVAX Comparison
Compare LSTA & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- EVAX
- Stock Information
- Founded
- LSTA 1980
- EVAX 2008
- Country
- LSTA United States
- EVAX Denmark
- Employees
- LSTA N/A
- EVAX N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSTA Health Care
- EVAX Health Care
- Exchange
- LSTA Nasdaq
- EVAX Nasdaq
- Market Cap
- LSTA 20.0M
- EVAX 16.3M
- IPO Year
- LSTA N/A
- EVAX 2021
- Fundamental
- Price
- LSTA $2.07
- EVAX $1.69
- Analyst Decision
- LSTA Strong Buy
- EVAX Strong Buy
- Analyst Count
- LSTA 1
- EVAX 2
- Target Price
- LSTA $15.00
- EVAX $10.00
- AVG Volume (30 Days)
- LSTA 9.1K
- EVAX 65.8K
- Earning Date
- LSTA 05-08-2025
- EVAX 05-27-2025
- Dividend Yield
- LSTA N/A
- EVAX N/A
- EPS Growth
- LSTA N/A
- EVAX N/A
- EPS
- LSTA N/A
- EVAX N/A
- Revenue
- LSTA $1,000,000.00
- EVAX $3,344,000.00
- Revenue This Year
- LSTA N/A
- EVAX $102.45
- Revenue Next Year
- LSTA N/A
- EVAX $200.44
- P/E Ratio
- LSTA N/A
- EVAX N/A
- Revenue Growth
- LSTA N/A
- EVAX 4480.82
- 52 Week Low
- LSTA $2.05
- EVAX $1.61
- 52 Week High
- LSTA $4.20
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- LSTA 34.86
- EVAX 36.47
- Support Level
- LSTA $2.31
- EVAX $1.67
- Resistance Level
- LSTA $2.46
- EVAX $1.97
- Average True Range (ATR)
- LSTA 0.15
- EVAX 0.12
- MACD
- LSTA -0.01
- EVAX 0.04
- Stochastic Oscillator
- LSTA 0.00
- EVAX 22.22
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.